All conditions under Subscription Agreement A have been fulfilled, and the transaction under Subscription Agreement A was completed on January 30, 2026. A total of 5.595 million subscription shares were successfully issued and allotted to Subscriber A at a subscription price of HK$5.36 per share. These 5.595 million subscription shares represent approximately 3.90% of the issued H-share capital immediately prior to the completion of Subscription Agreement A and about 2.34% of the existing issued share capital; following the completion of Subscription Agreement A, and after accounting for the allotment and issuance of these 5.595 million subscription shares, they represent approximately 3.75% of the enlarged issued H-share capital and about 2.29% of the enlarged total issued share capital. Following amicable negotiations, Subscriber B and the Company entered into a termination agreement on January 30, 2026 (after trading hours) to terminate Subscription Agreement B. Pursuant to the termination agreement, the parties to Subscription Agreement B are released and discharged from their respective obligations under it, and neither party shall make any claim against the other concerning any matter arising from or related to Subscription Agreement B. As Subscription Agreement B has been terminated, the total gross proceeds raised from Subscription Agreement A will be approximately HK$29.99 million, while the net proceeds will be approximately HK$29.73 million. After deducting all relevant expenses, the net price per subscription share is approximately HK$5.31. All net proceeds are intended to be used for the research and development, production, and commercialization of minimally invasive interventional products related to vascular intervention, respiratory intervention, and oncology intervention, as well as for potential overseas business expansion related to the commercialization of these products.